Introduction {#s1}
============

It was shown that the *p53* tumor suppressor gene serves a critical role in maintaining genomic stability during the cell cycle checkpoint in G1 and G2/M transition, and as an effector of DNA repair and apoptosis \[[@R01], [@R02]\]. Wild-type *p53* is needed to activate apoptosis in sensitive cells in response to DNA damage \[[@R01], [@R02]\]. These actions of *p53* are potentially critical in determining the effectiveness of ionizing radiation and/or chemotherapeutic agents. *p53* is mutated in a majority of human solid tumors and plays a central role in the cellular response to DNA-damaging treatments like ionizing radiation, chemotherapy or hypoxic stress \[[@R03]\]. Hypoxic stress also induces *p53* protein accumulation and *p53*-dependent apoptosis, but does not induce *p53*-dependent cell cycle arrest \[[@R03]\]. Loss of *p53* function may result in resistance to DNA-damaging agents, including ionizing radiation and hypoxic stress \[[@R01], [@R03]\]. Actually, mutations in the *p53* tumor suppressor gene have an impact on the clinical course of several human cancers: patients with cancers harboring *p53* mutations often have a worse prognosis than those with tumors harboring wild-type *p53* \[[@R01], [@R03]\]. Thus, the genetic and functional status of the *p53* gene is an important factor in guiding therapeutic strategies for cancer patients.

Meanwhile, intensity modulated radiotherapy (IMRT) and stereotactic irradiation have come into common usage as radiotherapy techniques for treating malignancies. Both modalities generally use multiple arc or fixed-portal radiation beams, and radiation beams are exposed intermittently. These techniques often require 30 min or longer in one treatment session for precise positioning of patients \[[@R04], [@R05]\]. Prolongation of irradiation time may reduce a radiation effect and evokes a major concern for the dose rate effect. Thus, it is needed to clarify the effect of the reduction of dose rate on the radio-sensitivity of tumors *in vivo*.

When using low linear energy transfer (LET) radiation, lowering the dose rate is thought to reduce late effects in normal tissue much more than it decreases tumor control. Thus, the "therapeutic ratio" increases as the dose rate decreases because the therapeutic ratio is equal to the ratio of tumor control to normal tissue complications. Furthermore, the difference between early and late effects for low dose-rate radiotherapy, as well as improving the therapeutic ratio, allows complete treatment in a short period of time, minimizing the effects of tumor repopulation. In other words, decreasing the dose rate increases the therapeutic ratio, limited only by tumor cell repopulation \[[@R06]\]. This is the primary rationale for low dose-rate radiotherapy using low-LET radiation.

On the other hand, many cells in solid tumors are quiescent in situ but still clonogenic \[[@R07]\]. The quiescent (Q) tumor cells are more resistant to low-LET radiation because of their larger hypoxic fraction and greater capacity to recover from potentially lethal damage (PLD) than proliferating (P) tumor cells. In addition, the rationale for low dose-rate radiotherapy does not take into account the response of Q intratumor cells at all.

In this study, we examined the characteristics of radio-sensitivity in the total (P + Q) and Q cell populations in solid tumors irradiated with irradiation with ^6^°Co or ^137^Cs γ-rays at various dose rates from very low to high dose rate. The responses of the total (= P + Q) and Q-cell populations in irradiated solid tumors were separately detected with the method for selectively detecting the response of Q cells in solid tumors \[[@R08]\], using two different tumor cell lines with identical genetic backgrounds except for *p53* status.

Materials and Methods {#s2}
=====================

Cells, tumors and mice {#s2a}
----------------------

The human head and neck squamous cell carcinoma cell line SAS (JCRB, Tokyo, Japan) was cultured at 37 °C in Dulbecco's modified Eagle's medium (DMEM) containing 20 mM 2-\[4-(2-hydroxyethyl)-1-piperazinyl\]ethanesulfonic acid (HEPES) and 12.5% fetal bovine serum in a conventional humidified 5% CO~2~ incubator. SAS cells show the phenotype of wild-type *p53* in radiation- and heat-induced signal transduction \[[@R9], [@R10]\]. Plasmid pC53-248, which contains an *mp53* gene (codon 248, from Arg to Trp) producing a dominant negative *mp53* protein, and plasmid pCMV-Neo-Bam, which contains a neo-resistance marker, were provided by B. Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD, USA). These plasmids were linearized with HindIII. Confluent SAS cells, approximately 2 × 10^6^ cells in a 75-cm^2^ flask, were trypsinized, and the resulting cell suspension in phosphate-buffered saline (PBS) (1 mL) was transferred into an electroporation chamber. Cells were supplemented with linearized DNA (10 µg/10 µL of pC53-248 or pCMV-Neo-Bam) and electroporated three times at 600 V. After standing for 30 min at room temperature, cells were plated onto dishes 10 cm in diameter in DMEM and incubated at 37 °C. Forty-eight hours later, cells were treated with G418 (geneticin, 200 µg/mL; Sigma Chemical Co., St Louis, MO, USA), an agent for selection of transfected clones, and then incubated at 37 °C for 14 days to allow colony formation. Colonies resistant to G418 were isolated with cloning cylinders. Through these manipulations, two stable transfectants SAS/*mp53* and SAS/*neo* were established. SAS/*neo* cells have a functionally wild-type *p53* protein, and SAS/*mp53* cells express a dominant-negative *p53* protein. The procedure used for transfection is described in detail elsewhere \[[@R9], [@R10]\].

Cells were collected from exponentially growing cultures, and approximately 5.0 × 10^5^ cells were inoculated subcutaneously into both hind legs of 6- to 7-week-old syngeneic female Balb/cA nude mice. Three weeks after inoculation, a tumor with a diameter of approximately 7 mm could be observed at each implanted site, whichever stable transfectant was used.

Meanwhile, in locally advanced or recurrent head and neck tumors, especially which are refractory to conventional cancer therapy including radiation therapy using low LET radiation X-rays, p53 status of the tumor cells is often mutated and the tumors often show hypoxic tendency rather than fresh and non-treated virgin tumors \[[@R11], [@R12]\].

Labeling with 5-bromo-2'-deoxyuridine (BrdU) {#s2b}
--------------------------------------------

Two weeks after tumor cell inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA, USA) containing BrdU dissolved in physiological saline (250 mg/mL) were implanted subcutaneously to label all P cells for 7 days. Administration of BrdU did not change the tumor growth rate. The tumors were approximately 7 mm in diameter on treatment. The labeling index (LI) after continuous labeling with BrdU was 48.4% (41.7-55.1%) (mean (95% confidence limit)) and 43.2% (37.0-49.4%) for SAS/*neo* and SAS/*mp53* tumor cells, respectively, and reached a plateau level at these stages. Therefore, in this study, we regarded tumor cells not incorporating BrdU after continuous labeling as Q cells.

Irradiation {#s2c}
-----------

After labeling with BrdU, the tumor-bearing mice underwent γ-ray irradiation. The irradiation was performed with the tumor-bearing mice held in a specially designed device made of acrylic resin with the tail or both arms and legs firmly fixed with an adhesive tape, without anesthesia.

γ-ray irradiation was performed with a^6^°Co γ-ray irradiator available at Institute for Integrated Radiation and Nuclear Science, Kyoto University at a dose rate of 2.5 Gy/min, such as conventionally used for high dose-rate irradiation (HDR). Middle dose-rate irradiation (MDR) was performed at a dose rate of 0.039 Gy/min by maintaining an appropriate distance between the ^6^°Co radiation source and the irradiated tumor-bearing mouse fixed within the specially constructed device. Meanwhile, low dose-rate irradiation (LDR) was carried out using ^137^Cs γ-ray irradiator with a source of 1,850 GBq at a dose rate of 0.00098 Gy/min also through maintaining an appropriate distance between the radiation source and the irradiated tumor-bearing mouse at Radiation Biology Center, Kyoto University.

According to the International Commission on Radiation Units and Measurements Report 58 concerning dosimetry in intracavitary brachytherapy for uterine cancer, high, middle and low dose-rate irradiation is defined as \> 0.2 Gy/min (12 Gy/h), 0.033 - 0.2 Gy/min (2 - 12 Gy/h) and \< 0.033 Gy/min (2 Gy/h), respectively \[[@R13]\]. Based on this criterion, the HDR, MDR and LDR used in the present study fit with the high dose-rate, middle dose-rate and low dose-rate irradiation, respectively.

Each irradiation group also included mice that had not been pretreated with BrdU. The tumors were then excised immediately or 9 h after irradiation.

Immunofluorescence staining of BrdU-labeled cells and observation of micronucleus (MN) formation {#s2d}
------------------------------------------------------------------------------------------------

The tumors were excised from mice given BrdU, minced, and trypsinized (0.05% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) in PBS at 37 °C for 15 min). The tumor cell suspensions were incubated for 48 h in tissue culture dishes containing complete medium and 1.0 µg/mL of cytochalasin-B to inhibit cytokinesis while allowing nuclear division, and the cultures were then trypsinized and cell suspensions were fixed. After the centrifugation of fixed cell suspensions, the cell pellet was resuspended with cold Carnoy's fixative. The suspension was then placed on a glass microscope slide and the sample was dried at room temperature. The slides were treated with 2 M hydrochloric acid for 45 min at room temperature to dissociate the histones and partially denature the DNA. The slides were then immersed in borax-borate buffer (pH 8.5) to neutralize the acid. BrdU-labeled tumor cells were detected by indirect immunofluorescence staining using monoclonal anti-BrdU antibody (Becton Dickinson, San Jose, CA, USA) and fluorescein isothiocyanate (FITC)-conjugated antimouse immunoglobulin G (whole molecule) antibody (Sigma, St Louis, MO, USA). To observe double staining of tumor cells with green-emitting FITC and red-emitting propidium iodide (PI), cells on the slides were treated with PI and monitored under a fluorescence microscope.

The MN frequency in BrdU-unlabeled cells (Q cells at irradiation) could be examined by counting the micronuclei in the binuclear cells that showed only red fluorescence. The MN frequency was defined as the ratio of the number of micronuclei in the binuclear cells to the total number of binuclear cells observed \[[@R08]\].

The ratios obtained in tumors not pretreated with BrdU indicated the MN frequency at all phases in the total (P + Q) tumor cell populations. More than 300 tumor cells and binuclear cells were counted to determine the apoptosis frequency and the MN frequency, respectively.

Needless to say, the induction of an MN requires division of the cell nucleus \[[@R14]\]. The duration of incubation with cytochalasin-B allowed Q cells to be recruited into the cell cycle. Thus, the optimal incubation period was determined so that the maximum rate of binuclear tumor cells could be observed. The frequencies of MN for BrdU-labeled cells were modified because the radiosensitization effect of the incorporated BrdU could potentially influence the frequencies in BrdU-labeled cells. Thus, the correct frequencies of BrdU-labeled cells without the BrdU effect are not able to be determined. During continuous labeling with BrdU, the shift of cells from P to Q population could result in labeled Q cells. These cells were excluded when we scored micronuclei in binuclear cells in tumor cells showing only red fluorescence by PI for DNA staining, because these cells were stained with FITC.

Cell survival assay {#s2e}
-------------------

The cell survival assay was also performed in mice given no BrdU using an *in vivo-in vitro* assay method. Tumors were disaggregated by stirring for 20 min at 37 °C in PBS containing 0.05% trypsin and 0.02% EDTA. The cell yield was 1.5 (1.2 - 1.8) × 10^7^/g and 3.4 (2.6 - 4.2) × 10^6^/g for SAS/neo and SAS/ mp53 tumors, respectively.

To confirm the stability of transfectants SAS/*neo* and SAS/*mp53*, part of the tumor cell suspensions obtained after irradiation and tumor cells from part of the colonies grown through the *in vivo-in vitro* assay method were subjected to western blotting analysis for *p53* and *Bax* proteins as described by Ota et al \[[@R15]\]. Not only the level, but also the function of *p53* protein could be detected because the *bax* gene is a target of the *p53* gene. As a result, it was confirmed that the *p53* status of each transfectant was not changed by these experimental procedures. Three mice were used to assess each set of conditions and each experiment was repeated three times. To examine the differences between pairs of values, Student's *t*-test was used when variances of the two groups could be assumed to be equal; otherwise the Welch *t*-test was used. *P* values were from two-sided tests.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} shows the plating efficiencies for the total tumor cell population and the MN frequencies without radiation for the total and Q cell populations in each tumor. Overall, SAS/*mp53* tumor cells showed significantly lower plating efficiency in the total cell populations and significantly higher MN frequencies in both the total and Q cell populations (P \< 0.05) than SAS/*neo* tumor cells. Further, Q cells showed significantly higher MN frequencies than the total cell population under each set of conditions in each tumor (P \< 0.05).

###### Plating Efficiency and Micronucleus Frequency at 0 Gy

                             Total tumor cells   Quiescent cells
  -------------------------- ------------------- -----------------
  SAS/*neo*                                      
    Plating efficiency (%)   45.5 ± 8.9^a^       
    Micronucleus frequency   0.038 ± 0.006       0.056 ± 0.007
  SAS/*mp53*                                     
    Plating efficiency (%)   23.5 ± 4.1          
    Micronucleus frequency   0.072 ± 0.008       0.111 ± 0.010

^a^Mean ± standard error (n = 6).

The clonogenic cell survival curves for total tumor cell populations immediately and 9 h after γ-ray irradiation with HDR and immediately after γ-ray irradiation with MDR and LDR are shown in [Figure 1](#F1){ref-type="fig"}. On the whole, SAS/*mp53* tumor cells were more radioresistant than SAS/*neo* tumor cells except under LDR. The increase in the surviving fraction (SF) with the 9-h delayed assay, that is, PLDR, and the increase in the SF after MDR or LDR were observed more clearly in SAS/*neo* than in SAS/*mp53*.

![Surviving fractions following γ-ray irradiation. The clonogenic cell survival curves for total tumor cell populations immediately and 9 h after γ-ray irradiation with high dose-rate irradiation (HDR) and immediately after γ-ray irradiation with middle dose-rate irradiation (MDR) and low dose-rate irradiation (LDR) are shown. The left and right panels show SAS/*neo* and SAS/*mp53* tumor cells, respectively. Bars represent standard errors (n = 6).](jocmr-10-815-g001){#F1}

The net micronucleus frequencies for total and Q-cell populations immediately and 9 h after γ-ray irradiation with HDR and immediately after γ-ray irradiation with MDR and LDR are shown in [Figure 2](#F2){ref-type="fig"}. For baseline correction, we used the net MN frequency to exclude the MN frequency in non-irradiated control tumors. The net MN frequency was the MN frequency in the irradiated tumors minus that in the non-irradiated tumors. On the whole, Q tumor cells were more radioresistant than the total tumor cell population. The decrease in the net MN frequency with the 9-h delayed assay and the decrease in the net MN frequency after MDR or LDR were more obvious in SAS/*neo* and Q cells than in SAS/*mp53* and the total cell population, respectively.

![Net micronucleus frequencies following γ-ray irradiation. The net micronucleus frequencies for total (solid lines, open symbols) and quiescent (dotted lines, solid symbols) cell populations immediately and 9 h after γ-ray irradiation with high dose-rate irradiation (HDR) and immediately after γ-ray irradiation with middle dose-rate irradiation (MDR) and low dose-rate irradiation (LDR) are shown. The left and right panels show SAS/*neo* and SAS/*mp53* tumor cells, respectively. Bars represent standard errors (n = 6).](jocmr-10-815-g002){#F2}

To evaluate the recovery capacity from the damage induced by HDR or during MDR or LDR in total and Q-cell populations within these two tumors, dose modifying factors were calculated in both cell populations at various endpoints using the data given in [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} ([Table 2](#T2){ref-type="table"}). Overall, regardless of the cell populations, SAS/*mp53* tumor cells showed little recovery capacity under any irradiation conditions. In SAS/*neo* tumor cells, whether 9 h after HDRI or after MDR or LDR, the recovery capacities following γ-ray irradiation were significantly greater in Q-cell populations than total cell populations (P \< 0.05). In these two tumors, the recovery capacities in both total and Q tumor cell populations following γ-ray irradiation increased in the following order of 9 h after HDR \< MDR \< LDR.

###### Dose-Modifying Factors Due to a Delayed Assay or Reduced Irradiation Dose Rate^a^

                                     HDR             MDR           LDR
  ---------------------------------- --------------- ------------- ------------
  Surviving fraction = 0.2                                         
    SAS/*neo*                        1.5 ± 0.15^b^   1.6 ± 0.15    2.1 ± 0.2
    SAS/*mp53*                       1.1 ± 0.1       1.2 ± 0.1     1.3 ± 0.1
  Net micronucleus frequency = 0.1                                 
    Total tumor cells                                              
      SAS/*neo*                      1.4 ± 0.1       1.45 ± 0.1    1.8 ± 0.15
      SAS/*mp53*                     1.05 ± 0.1      1.1 ± 0.1     1.15 ± 0.1
    Quiescent cells                                                
      SAS/*neo*                      1.55 ± 0.15     1.65 ± 0.15   1.85 ± 0.2
      SAS/*mp53*                     1.05 ± 0.1      1.1 ± 0.1     1.2 ± 0.1

^a^The ratio of the dose of radiation necessary to obtain each end-point with a delayed assay or reduced dose-rate irradiation to that needed to obtain each end-point with an assay immediately after high dose-rate irradiation. ^b^Mean ± standard error (n = 6).

To compare the cell survival curve between these two tumor cells, we calculated the dose ratios for SAS/*mp53* tumor cells relative to SAS/*neo* tumor cells ([Table 3](#T3){ref-type="table"}). The factors were calculated by comparing the radiation doses to obtain SF = 0.2 in SAS/*mp53* tumor cells with the doses required in SAS/*neo* tumor cells. Following γ-ray irradiation, the values were decreased in the order of right after HDR \> 9 h after HDR \> MDR \> LDR because of the apparent recovery from radiation-induced damage in SAS/*neo* tumor cells, compared with SAS/*mp53* tumor cells that showed little recovery capacity.

###### Dose-Modifying Factors for SAS/*mp53* Relative to SAS/*neo* Tumor Cells^a^

  HDR                        HDR          MDR          LDR
  -------------------------- ------------ ------------ -----------
  Surviving fraction = 0.2                             
  1.4 ± 0.1^b^               1.05 ± 0.1   1.05 ± 0.1   1.0 ± 0.1

^a^The ratio of the physical radiation dose of external beams necessary to obtain each end-point in SAS/*mp53* tumor cells to that needed to obtain each end-point in SAS/*neo* tumor cells. ^b^Mean ± standard error (n = 6).

[Table 4](#T4){ref-type="table"} shows the dose ratios of Q cells relative to total tumor cell populations; these factors were used to compare the radiation doses necessary to obtain the net MN frequency of 0.1 in Q cells with the doses required in the total tumor cell populations. All the values of the dose ratios were significantly larger than 1.0 (P \< 0.05), and the values increased in the following order of right after HDR \< 9 h after HDR \< MDR \< LDR in both SAS/*neo* and SAS/*mp53* tumor cells probably due to a greater recovery capacity in Q cells than in the total cell population.

###### Dose-Modifying Factors for Quiescent Relative to Total Tumor Cells^a^ at Net Micronucleus Frequency of 0.1

  HDR            HDR         MDR          LDR
  -------------- ----------- ------------ -------------
  SAS/*neo*                               
  2.2 ± 0.2^b^   2.2 ± 0.2   2.4 ± 0.25   2.45 ± 0.25
  SAS/*mp53*                              
  1.85 ± 0.2     1.9 ± 0.2   1.9 ± 0.2    1.95 ± 0.2

^a^The ratio of the dose of radiation necessary to obtain each end-point in the quiescent cell population to that needed to obtain each end-point in the total tumor cell population. ^b^Mean ± standard error (n = 6).

Discussion {#s4}
==========

PLD is the component of radiation damage that can be modified by post-irradiation conditions \[[@R06]\]. Under ordinary circumstances, PLD causes cell death. Changing cellular growth conditions or the microenvironment around cells influences the expression of PLD or PLDR, and thereby influences sensitivity to radiation. PLDR is favored by conditions that maintain cells without encouraging or allowing them to divide. Conditions found in solid tumors, regions of which may be far from blood vessels and low in glucose and oxygen, have a low extracellular pH, and show high concentrations of cellular waste products, may prevent cells from proliferating and thereby promote the repair of PLD. Extensive studies on PLDR suggest that DNA double-stranded breaks (*dsb*s) are potentially lethal lesions that can be converted into lethal damage \[[@R16]\]. It was reported that the conversion of potentially lethal lesions into lethal lesions might be a *p53*-dependent process and that PLDR was proportional to the percentage of radiation-induced DNA *dsb*s rejoined in 1 h in the cell lines with a normal *p53* \[[@R17], [@R18]\].

Dose rate is one of the principal factors determining the biological consequences of a given absorbed dose. As the dose rate is lowered and the exposure time extended, the biological effect of a given dose is generally reduced. The dose-rate effect, which is very important in radiotherapy, results from the repair of sublethal damage (SLD) that occurs during a long radiation exposure \[[@R06]\]. Incidentally, SLD repair is the operational term for the increase in cell survival that is observed if a given radiation dose is split into two fractions separated by a time interval. Because continuous LDR may be considered to be an infinite number of infinitely small fractions, the survival curve under these conditions also would be expected to have no shoulder and to be shallower than for a single acute exposure \[[@R06]\]. It was also reported that a normal functioning *p53* gene is indispensable for a repair of DNA damage induced under LDR \[[@R19], [@R20]\]. Further, it was also reported that radiation-induced damage is more easily repaired at the time of low dose-rate than high dose-rate exposure, and as a result, that carcinogenesis due to radiation exposure can be more efficiently suppressed at the time of low dose rate than high dose rate exposure \[[@R21]\].

Following γ-ray irradiation, concerning whether PLDR after HDR or the repair during MDR or LDR, SAS/*neo* showed an apparent repair phenomenon in both total and Q-cell populations ([Fig. 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Especially, Q cells in solid tumors with wild-type *p53* exhibited greater capacities of the repair than the total cell population, probably due to the intratumor conditions, that is, hypoxic, nutrition-depleted, and low pH circumstances, where Q cells came into existence \[[@R07]\] ([Fig. 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). In contrast, no apparent repair was observed in total or Q-cell populations within *p53*-mutated tumors ([Fig. 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

Two major pathways for the repair of potentially lethal DNA *dsb*s exist in mammalian cells. The non-homologous end-joining (NHEJ) pathway is imprecise, error-prone and mutagenic, and mutant cell lines lacking key components of this pathway all exhibit impaired kinetics of DNA *dsb* repair and exquisite radio-sensitivity \[[@R22], [@R23]\]. Homologous recombination (HR) is a more precise (error-free) repair mechanism and is more important for the repair of *dsb*s in late-S and G2 when a sister chromatid is available for the recombination reaction. Cell lines with defects in HR also exhibit increased radio-sensitivity and decreased fidelity of repair \[[@R22], [@R24]\].

A cellular safeguard against genetic destabilization is activation of the *p53* tumor suppressor protein, which commonly responds to DNA damage signals by inducing apoptosis or regulating the cell cycle including DNA damage repair \[[@R22], [@R25]\]. As also shown in our previous report \[[@R26]\], the net MN frequencies in SAS/*neo* tumor cells were lower than those in SAS/*mp53* tumor cells under all conditions (P \< 0.05), probably resulting from exclusion of a higher number of radiation-induced apoptotic SAS/*neo* cells than SAS/*mp53* cells.

Loss-of-function of wild-type *TP53* can result in loss of the G1/S cell-cycle checkpoint and an increase in HR \[[@R22], [@R25]\]. As *p53* seems to interact with RAD51, the absence of normal *p53* function is thought to enhance RAD51-mediated DNA pairing activity and HR, due to overexpression of RAD51 out of regulation by normal *p53* \[[@R22], [@R25]\]. Thus, HR is thought to be a principal mechanism of DNA *dsb* repair in SAS/*mp53* cells. The very small repair capacity of SAS/*mp53* cells *in vivo* may show that the repair in solid tumors with a mutant *p53* is thought to be mainly due to, if anything, the NHEJ rather than HR.

After γ-ray irradiation, the dose ratios for SAS/*mp53* cells relative to SAS/*neo* cells showed that SAS/*mp53* tumor cells within solid tumors are less radiosensitive than SAS/*neo* tumor cells ([Table 3](#T3){ref-type="table"}). This is consistent with reports that tumor cells with a mutant *p53* gene were more radioresistant than those with a wild-type *p53* gene \[[@R26]\]. Since apparent repair phenomena could be observed in solid tumors with a wild-type *p53* gene, the difference in sensitivity between SAS/*neo* and SAS/*mp53* was slightly reduced without significant differences after repair. This finding may be some advantage for controlling malignant tumors, which include significantly more *p53*-mutated cells than normal tissues \[[@R02]\] in terms of controlling solid tumors as homogeneously as possible.

Nine hours was already shown to be long enough to repair the initial radiation-induced damage after γ-ray irradiation, and the capacity for PLDR was also shown to be greater in Q cells than in the total cell population \[[@R27]\]. In addition, the reduction in sensitivity caused by a decreasing dose rate under γ-ray irradiation, which has been ascribed to SLD repair during infinite split-dose irradiation and PLDR during reduced dose-rate irradiation \[[@R06]\], was also shown to be more marked than PLDR during 9 h after HDR following γ-ray irradiation and more clearly observed in Q cells than in total cells within solid tumors \[[@R28]\]. The reduction in sensitivity caused by a decreasing dose rate under γ-ray irradiation, which was more marked than PLDR during the 9 h after HDR and more clearly observed in Q cells than in total cells \[[@R28]\], produced greater differences in sensitivity between the total and Q cells to γ-ray irradiation than 9 h after HDR. This means that requirement to repress the difference in sensitivity between total and Q tumor cells especially in solid tumors with wild-type *p53* is getting larger and larger as irradiation dose rate decreases in terms of controlling solid tumors as a whole. In other words, it can be considered that the importance for suppressing the heterogeneity within solid tumors is getting larger as irradiation dose rate decreases. Based on our previous reports concerning the analysis of the characteristics of intratumor Q-cell population in response to conventional antitumor therapy \[[@R29]\], combined treatment with continuous administration of hypoxia-specific cytotoxin like tirapazamine, which can kill both acute and chronic hypoxic tumor cells, and mild temperature hyperthermia, which can release chronic hypoxia and increase drug distribution through increasing blood flow, is considered to be very effective in terms of controlling conventional anticancer therapy-resistant intratumor Q-cell population.

Solid tumors, especially human tumors, are thought to contain a high proportion of Q cells \[[@R07]\]. The presence of these cells is probably due, in part, to a microregional deficiency in the concentrations of oxygen, glucose and other nutritional factors in the tumors caused by poor and heterogeneous tumor vascular supply \[[@R07]\]. This deficiency might promote MN formation in Q tumor cells at 0 Gy ([Table 1](#T1){ref-type="table"}) \[[@R07], [@R30]\]. As shown here, Q cells have lower radiosensitivity than P cells in solid tumors *in vivo*, irrespective of the *p53* status of tumor cells ([Table 4](#T4){ref-type="table"}) \[[@R27]\]. This means that more Q cells survive after radiotherapy than P cells. Consequently, the control of Q cells also has a great impact on the outcome of radiotherapy. Thus, from the viewpoint of the tumor cell-killing effect including intratumor Q-cell control, a treatment modality for enhancing the Q-cell response has to be considered.

Conclusions {#s4a}
-----------

To secure controlling solid tumors as a whole, difference in sensitivity between total and Q tumor cells especially in solid tumors with wild-type *p53* has to be suppressed as irradiation dose rate decreases, for instance, through employing combined method for enhancing the response of Q tumor cells.
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